Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer

Centre Oscar Lambret385 enrolled

Overview

This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer

Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer, and largely affects the long term survival. Addiction intervention programs should be personalized according to the patient's profile, with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use. As of today, the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer. The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer. The secondary objectives of the study are: * to depict the rate of alcohol users 12 months after the initial diagnosis of a H\&N cancer * to depict the rate of tobacco smokers at cancer diagnosis * to depict the rate of alcohol users at cancer diagnosis * to determine the social, motivational, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC. * to determine the social, psychiatric, tobacco-related, alcohol-related, and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first H\&N cancer

Study Type

OBSERVATIONAL

Enrollment

385

Conditions

Head and Neck Cancer Lung Cancer

Interventions

physician assessmentBEHAVIORAL

* Socio-economic conditions and general features: educational level, professional status... * Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level... * in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test... * Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months... * Assessment of current use of cannabis using the Cannabis Abuse Screening Test * Psychiatric assessment using the MINI 5.0

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * first head and neck or lung cancer * first support * age ≥ 18 * patient covered by health insurance * signed informed consent Exclusion Criteria: * prior lung or head and neck cancer * History of another cancer \<5 years, not evolutive and untreated at baseline (carcinoma of the cervix, or basal cell carcinoma of the skin properly treated are allowed). The presence of a second discovery tumor location at the same time as the lung or head and neck cancer, is not a criteria for non-inclusion * mesothelioma and oesophageal cancer * unable to undergo trail medical follow up (geographical, social and psychological reasons) * pregnant or nursing women * patient under guardianship

Locations (3)

Centre Hospitalier Régional et Universitaire - Hopital CALMETTE

Lille, France

Centre Hospitalier Régional et Universitaire - Hopital HURIEZ

Lille, France

Oscar Lambret Center

Lille, France

Outcomes

Primary Outcomes

tobacco consumption

reported tobacco smoking

Time frame: at 12 months

Secondary Outcomes

tobacco smoking

frequency tobacco consumption

Time frame: at baseline, 3 and 6 months

alcohol drinking

frequency of alcohol consumption

Time frame: at baseline, 3, 6 and 12 months

progression free survival

median time between date of inclusion and date of first progression

Time frame: at 12 months

overall survival

median time between date of inclusion and date of death

Time frame: at 12 months

sociodemographic, cancer-related, tobacco-related, alcohol-related, and psychiatric characteristics

Time frame: at baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.